Optimization of persistent bronchial asthma therapy in children: first step is important
https://doi.org/10.21518/2079-701X-2013-1-1-55-59
Abstract
The end of the last century was characterized by rapid growth of atopy all over the world. Large-scale epidemiological studies of allergic diseases in children undertaken at the turn of the XX-XXI centuries showed that asthma is the most common chronic disorder in children. Over the last decade no similar studies were carried out, so it is impossible to evaluate the changes in trends; however, certain observations led to the conclusion that in European countries the frequency of asthma symptoms has stabilized or even declined.
About the Authors
E. G. Kondyurina
Новосибирский государственный медицинский университет Минздрава России
Russian Federation
Russian Federation
V. V. Zelenskaya
Новосибирский государственный медицинский университет Минздрава России
Russian Federation
Russian Federation
O. A. Ryabova
Новосибирский государственный медицинский университет Минздрава России
Russian Federation
Russian Federation
References
1. Национальная программа «Бронхиальная астма у детей. Стратегия лечения и профилактика». 4-е изд., испр. и доп. М., 2012. 184 с.
2. Cochrane G.M. Compliance and outcomes in patients with asthma. Drugs 1996; 52 (Suppl. 6): 12S–19S.
3. Howell G. Nonadherence to medical therapy in asthma: risk factors, barriers, and strategies for improving // J. Asthma. 2008. Vol.45. 9. P. 723–729.
4. Dumitru C., Chan S.M., Turcanu V. Role of leukotriene receptor antagonists in the management of pediatric asthma: an update/ Paediatr Drugs. 2012 Oct 1;14(5): 317-30.
5. Goldbart A.D., Greenberg-Dotan S., Tal A. Montelukast for children with obstructive sleep apnea: a double-blind, placebo-controlled study. Pediatrics. 2012 Sep; 130(3): e575-80.
6. Zhang L., Axelsson I., Chung M. et al. Dose response of inhaled corticosteroids in children with persistent asthma: a systematic review. Pediatrics. 2011 Jan; 127(1): 129-38.
7. National asthma education and prevention program / Expert panel report 3. Guidelines for the diagnosis and management of asthma: NIH Publication N 08-5846, October 2007. 61 p.
8. Tan R.A., Corren J. Mometasone furoate in the management of asthma: a review // er. Clin. Risk Manag. 2008. Vol. 4. 6. P. 1201– 1208.9 Sahasranaman S., Issar M., Hochhaus G. Metabolism of mometasone furoate and biological activity of the metabolites // Drug Metab. Dispos. 2006. Vol. 34. 2. P. 225–233.
9. Miller-Larsson A., Axelsson B.-O., Brattsand R. et al. Relative lipophilicity of budesonide, fluticasone propionate, mometasone furoate, and ciclesonide. Preference of variable lipophilicity in airways versus systemic compartment // Am. J. Respir. Crit Care Med. 2003. Vol. 167. Suppl. 7. Abstract A773.
10. Derendorf H., Nave R., Drollman A. et al. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma // Eur. Respir. J. 2006. Vol. 28. 5. P. 1042–1050
Review
For citations:
Kondyurina EG, Zelenskaya VV, Ryabova OA. Optimization of persistent bronchial asthma therapy in children: first step is important. Meditsinskiy sovet = Medical Council. 2013;(1-1):55-59. (In Russ.) https://doi.org/10.21518/2079-701X-2013-1-1-55-59
Views:
459
Email this article 